{"id":239749,"date":"2026-06-26T22:23:57","date_gmt":"2026-06-27T03:23:57","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/06\/survival-outcomes-and-a-prognostic-nomogram-in-egfr-mutant-non-small-cell-lung-cancer-with-leptomeningeal-metastasis-a-real-world-cohort-study"},"modified":"2026-06-26T22:23:57","modified_gmt":"2026-06-27T03:23:57","slug":"survival-outcomes-and-a-prognostic-nomogram-in-egfr-mutant-non-small-cell-lung-cancer-with-leptomeningeal-metastasis-a-real-world-cohort-study","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/06\/survival-outcomes-and-a-prognostic-nomogram-in-egfr-mutant-non-small-cell-lung-cancer-with-leptomeningeal-metastasis-a-real-world-cohort-study","title":{"rendered":"Survival outcomes and a prognostic nomogram in EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis: a real-world cohort study"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/survival-outcomes-and-a-prognostic-nomogram-in-egfr-mutant-non-small-cell-lung-cancer-with-leptomeningeal-metastasis-a-real-world-cohort-study.jpg\"><\/a><\/p>\n<p>Leptomeningeal metastasis (LM) carries a poor prognosis in EGFR-mutant non-small cell lung cancer (NSCLC). This study aims to explore clinical features and survival outcomes and develop a nomogram for overall survival (OS) in this population.<\/p>\n<p>We retrospectively enrolled 288 EGFR-mutant NSCLC patients with LM from Fujian Cancer Hospital (January 2019\u2013March 2024). Prognostic variables were selected by LASSO regression followed by multivariable Cox proportional hazards modeling. Internal validation used 1000-iteration bootstrap resampling. Model performance was assessed by the time-dependent area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis.<\/p>\n<p>Median OS was 16.2 months. Before LM, 71.5% of patients received third-generation EGFR tyrosine kinase inhibitors (TKIs), and 76.7% received third-generation EGFR-TKI therapy after LM. Eight variables were identified by LASSO-Cox regression: ECOG performance status (PS), prior lines of systemic therapy, cranial MRI findings, third-generation EGFR-TKI therapy before and after LM, antiangiogenic therapy after LM, chemotherapy after LM, and CNS radiotherapy after LM. Post-LM third-generation EGFR-TKI therapy was the strongest treatment-associated prognostic factor (HR = 2.23; p 0.001), with survival benefit maintained regardless of prior third-generation EGFR-TKI exposure (prior-exposed: HR = 0.60, p = 0.029; TKI-na\u00efve: HR = 0.18, p 0.001). The nomogram demonstrated good discrimination (AUC: 0.777, 0.778, and 0.742 for 6-, 12-, and 18-month OS; C-index: 0.716).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Leptomeningeal metastasis (LM) carries a poor prognosis in EGFR-mutant non-small cell lung cancer (NSCLC). This study aims to explore clinical features and survival outcomes and develop a nomogram for overall survival (OS) in this population. We retrospectively enrolled 288 EGFR-mutant NSCLC patients with LM from Fujian Cancer Hospital (January 2019\u2013March 2024). Prognostic variables were selected [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-239749","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=239749"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/239749\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=239749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=239749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=239749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}